Cardiovascular Drugs Practice Questions

Q: Which of the following conditions precipitates Digoxin toxicity?

Hypokalemia. **Explanation:**Digoxin works by inhibiting the **Na⁺/K⁺-ATPase pump** on the myocardial cell membrane. Under normal physiological conditions, potassium (K⁺) ions compete with Digoxin for the same binding site on this ATPase pump. In **Hypokalemia (Option A)**, there is less extracellular potassium available to compete for these binding sites. This allows more Digoxin to bind to the pump, leading to excessive inhibition and an exaggerated pharmacological effect, which precipitates **Digoxin toxicity** [2]. Even "normal" therapeutic levels of Digoxin can become toxic in the presence of low potassium. **Analysis of Incorrect Options:** * **Hyperkalemia (Option B):** High potassium levels increase competition for the binding site, effectively reducing Digoxin’s binding and action. While hyperkalemia can *antagonize* Digoxin, it does not precipitate toxicity [1] (though severe toxicity itself can cause hyperkalemia due to pump paralysis). * **Hypernatremia (Option C) & Hyperphosphatemia (Option D):** Sodium and phosphate levels do not directly compete with Digoxin at its binding site on the Na⁺/K⁺-ATPase pump and are not primary triggers for toxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Electrolyte Triad of Toxicity:** Digoxin toxicity is precipitated by **Hypokalemia, Hypomagnesemia, and Hypercalcemia** ("Hi-Cal, Low-Mag, Low-K") [2]. * **ECG Changes:** The most common initial sign of toxicity is **PVCs** (Premature Ventricular Contractions). The most characteristic arrhythmia is **Atrial Tachycardia with AV block**. * **Visual Disturbance:** Patients may report **Xanthopsia** (yellow-green halos around lights). * **Antidote:** Digoxin-specific antibody fragments (**DigiFab**).

Q: All of the following statements are true about quinidine except?

It has no effect on myocardial K+ channels.. Explanation: Quinidine is a prototype Class IA antiarrhythmic drug. To answer this question, one must understand the "Vaughan-Williams classification" and the specific electrophysiological properties of Class IA agents [2]. 1. Why Option B is the correct answer (The False Statement): Contrary to the statement, Quinidine does block myocardial K+ channels (specifically the delayed rectifier current, $I_{Kr}$) [1]. By blocking potassium channels, it prolongs the action potential duration (APD) and the effective refractory period (ERP). This K+ channel blockade is also responsible for the side effect of QT interval prolongation, which can predispose patients to Torsades de Pointes [3]. 2. Analysis of Incorrect Options (True Statements): * Option A & C: Quinidine is a sodium (Na+) channel blocker [1]. It shows "state-dependency," meaning it binds preferentially to channels in the open or activated state. Because it binds more effectively when channels are firing frequently, it exhibits "frequency-dependent" (or use-dependent) blockade, making it more effective in tachyarrhythmias [2]. * Option D: Class IA drugs are characterized by intermediate dissociation kinetics. They delay the recovery of Na+ channels from the inactivated state, thereby increasing the threshold for excitability. High-Yield Clinical Pearls for NEET-PG: * Cinchonism: A classic side effect triad of tinnitus, headache, and dizziness [1]. * Vagolytic Effect: Quinidine has atropine-like (antimuscarinic) properties, which can paradoxically increase AV conduction. * Drug Interaction: Quinidine reduces the renal clearance of Digoxin, leading to digoxin toxicity. * ECG Changes: Widened QRS (Na+ block) and prolonged QT (K+ block).

Q: Postural hypotension and failure of ejaculation is most commonly seen in treatment with?

Guanethedine. **Explanation:** **Guanethidine** is the correct answer because it is an **adrenergic neuron blocker**. It works by inhibiting the release of norepinephrine from postganglionic sympathetic nerve endings and displacing stored norepinephrine, leading to a gradual depletion of catecholamines [1]. 1. **Postural Hypotension:** By blocking the sympathetic outflow, Guanethidine prevents the compensatory vasoconstriction required when a person stands up, leading to a significant drop in blood pressure [1], [2]. 2. **Failure of Ejaculation:** Ejaculation is a sympathetic-mediated process ("S" for Sympathetic = Shoot). Guanethidine’s blockade of peripheral sympathetic nerves prevents the contraction of the vas deferens and seminal vesicles, leading to ejaculatory failure. **Analysis of Incorrect Options:** * **Minoxidil:** A potent direct-acting vasodilator (K+ channel opener). It typically causes reflex tachycardia and fluid retention, not postural hypotension or ejaculatory issues. * **Propranolol:** A non-selective beta-blocker. While it can cause erectile dysfunction (impotence), it does not typically cause failure of ejaculation or significant postural hypotension (as alpha-receptors remain intact for vasoconstriction). * **Sodium Nitroprusside:** A balanced vasodilator (arteriolar and venous) used in hypertensive emergencies. While it can cause a rapid drop in BP, it is administered IV in a controlled setting and is not associated with chronic ejaculatory failure. **High-Yield Clinical Pearls for NEET-PG:** * **"Triple Action" of Guanethidine:** It inhibits release, inhibits reuptake (Uptake-1), and depletes stores of NE [1]. * **Drug Interaction:** Tricyclic Antidepressants (TCAs) and Cocaine block the uptake of Guanethidine into the neuron, reversing its antihypertensive effect [1]. * **Mnemonic:** Sympathetic = **S**hoot (Ejaculation); Parasympathetic = **P**oint (Erection). Guanethidine affects the "Shoot."

Q: Which of the following is the best inotropic drug for use in right heart failure?

Milrinone. **Explanation:** The management of right heart failure (RHF) requires a drug that simultaneously increases myocardial contractility (inotropy) and reduces the afterload on the right ventricle by decreasing pulmonary vascular resistance (PVR). **Why Milrinone is the Correct Answer:** Milrinone is a **Phosphodiesterase-3 (PDE3) inhibitor**. It works by increasing intracellular cAMP in cardiac and smooth muscle cells. This leads to two synergistic effects: 1. **Inotropy:** Increases cardiac contractility. 2. **Inodilatation:** Causes potent systemic and, more importantly, **pulmonary vasodilation**. By reducing pulmonary artery pressure, Milrinone decreases the workload of the thin-walled right ventricle, making it the "gold standard" inotropic agent for RHF and pulmonary hypertension. **Analysis of Incorrect Options:** * **Dobutamine (Option A):** While an excellent inotrope ($\beta_1$ agonist), it has less predictable effects on pulmonary vascular resistance compared to Milrinone and can increase myocardial oxygen demand significantly. * **Dopamine (Option B):** At higher doses, it causes $\alpha_1$-mediated vasoconstriction, which can increase pulmonary artery pressures and worsen the strain on the right ventricle. * **Digoxin (Option C):** It has a slow onset of action and weak inotropic effects; it is not used for the acute management of right heart failure. **High-Yield Clinical Pearls for NEET-PG:** * **Milrinone Side Effect:** The most common side effect is **hypotension** due to systemic vasodilation; it may require a concurrent vasopressor (like Noradrenaline). * **Renal Clearance:** Milrinone is renally excreted; doses must be adjusted in patients with renal impairment. * **Inodilator Concept:** Remember that Milrinone and Levosimendan are classified as "inodilators." * **Right Ventricle (RV):** Unlike the left ventricle, the RV is highly sensitive to afterload; therefore, reducing PVR is the cornerstone of RHF therapy.

Q: Which one of the following antihypertensive drugs is contraindicated in pregnancy?

Furosemide. ### Explanation **Correct Option: D. Furosemide** **Why Furosemide is Contraindicated:** Furosemide is a potent loop diuretic. In pregnancy, it is generally avoided because it can cause **placental hypoperfusion**. Diuretics reduce maternal plasma volume, which may interfere with the physiological volume expansion necessary for a healthy pregnancy. This can lead to decreased uterine blood flow, potentially causing fetal growth restriction or neonatal complications. Additionally, it crosses the placental barrier and can cause electrolyte imbalances in the fetus. **Analysis of Incorrect Options:** * **A. Alpha-methyldopa:** This is a centrally acting alpha-2 agonist and has traditionally been the **drug of choice (DOC)** for chronic hypertension in pregnancy due to its long-term safety profile for both mother and fetus. * **B. Hydralazine:** A direct vasodilator used primarily in the management of **acute hypertensive emergencies** in pregnancy (e.g., severe pre-eclampsia). It is considered safe for rapid blood pressure reduction. * **C. Nifedipine:** A calcium channel blocker (dihydropyridine) that is frequently used as a first-line oral agent for maintenance therapy and as a tocolytic to delay preterm labor. **High-Yield NEET-PG Pearls:** 1. **Absolute Contraindications:** ACE inhibitors (e.g., Enalapril) and ARBs (e.g., Losartan) are strictly contraindicated due to **teratogenicity** (renal dysgenesis, skull hypoplasia, and oligohydramnios). Direct Renin Inhibitors (Aliskiren) and Statins are also contraindicated. 2. **Safe Antihypertensives (Mnemonic: Better Mother Love Next-generation):** **B**eta-blockers (Labetalol), **M**ethyldopa, **L**abetalol (often DOC now), **N**ifedipine. 3. **Labetalol** is currently preferred over Methyldopa in many guidelines due to a faster onset and fewer side effects (like sedation).

Q: Which of the following is an active metabolite of another drug and is available as a separate drug for the treatment of angina?

Isosorbide mononitrate. **Explanation:** The correct answer is **Isosorbide mononitrate (ISMN)**. **1. Why Isosorbide mononitrate is correct:** Isosorbide dinitrate (ISDN) undergoes extensive first-pass metabolism in the liver, where it is converted into two active metabolites: **Isosorbide-2-mononitrate** and **Isosorbide-5-mononitrate**. Among these, Isosorbide-5-mononitrate is the major metabolite. It has been developed as a separate drug because it possesses **100% oral bioavailability** (unlike the parent drug ISDN) and a longer half-life, making it highly effective for the chronic prophylaxis of angina pectoris. **2. Why other options are incorrect:** * **Isosorbide dinitrate (ISDN):** This is the parent prodrug. While effective, it has low oral bioavailability (~20-25%) due to significant hepatic metabolism. * **Nitroglycerine (Glyceryl Trinitrate):** This is a parent drug, not a metabolite of another anti-anginal. It undergoes near-total first-pass metabolism, which is why it is typically administered sublingually for acute attacks. * **Propranolol:** This is a non-selective beta-blocker. While used in chronic angina to reduce myocardial oxygen demand, it is a parent drug and its active metabolite (4-hydroxypropranolol) is not marketed as a separate anti-anginal agent. **High-Yield Clinical Pearls for NEET-PG:** * **Bioavailability:** ISMN is the only organic nitrate that does not undergo significant first-pass metabolism (Bioavailability ≈ 100%). * **Nitrate Tolerance:** To prevent tolerance, a "nitrate-free interval" of 8–12 hours (usually at night) is mandatory. * **Drug Interaction:** Nitrates are strictly contraindicated with **Sildenafil** (PDE-5 inhibitors) due to the risk of severe, fatal hypotension. * **Monday Disease:** Chronic exposure to nitrates in ammunition factories leads to tolerance; loss of this tolerance over the weekend results in "Monday morning headaches" due to sudden vasodilation.

Q: Digitalis does not affect which parameter of the heart?

None of the above. **Explanation:** Digitalis (Digoxin) is a cardiac glycoside that exerts significant effects on multiple parameters of cardiac physiology. The correct answer is **"None of the above"** because Digitalis affects heart rate, contractility, and coronary blood flow. 1. **Contractility (Positive Inotropy):** Digitalis inhibits the **Na⁺/K⁺-ATPase pump**, leading to an increase in intracellular Na⁺. This reduces the activity of the Na⁺/Ca²⁺ exchanger, resulting in higher intracellular Ca²⁺ levels, which directly increases the force of myocardial contraction. 2. **Heart Rate (Negative Chronotropy):** Digitalis increases **vagal (parasympathetic) tone** and decreases sympathetic activity. This slows the firing of the SA node and prolongs conduction through the AV node, effectively reducing the heart rate. 3. **Coronary Blood Flow:** In a healthy heart, Digitalis can cause mild vasoconstriction. However, in a failing heart, the increase in cardiac output and the reduction in ventricular wall tension (due to better emptying) lead to an indirect **improvement in coronary perfusion**. **Why other options are incorrect:** Options A, B, and C are all parameters significantly altered by Digitalis therapy. Since the drug influences all three, "None of the above" is the only logical choice. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Inhibition of Na⁺/K⁺-ATPase (the "Digitalis Receptor"). * **ECG Changes:** Characterized by the **"Reverse Tick" sign** or "Sagging" ST-segment depression. * **Toxicity:** Hypokalemia predisposes to Digoxin toxicity. The most common arrhythmia is **Ventricular Bigeminy**, while the most characteristic is **Atrial Tachycardia with AV block**. * **Therapeutic Range:** Narrow (0.5–2 ng/mL).

Q: Use of Phosphodiesterase Inhibitors for erectile dysfunction is contraindicated in which of the following conditions?

Unstable/symptomatic angina. The correct answer is **Unstable/symptomatic angina**. Phosphodiesterase-5 (PDE-5) inhibitors (e.g., Sildenafil, Tadalafil) cause systemic vasodilation by increasing cGMP levels. In patients with unstable angina, this can lead to a significant drop in blood pressure and a reflex increase in heart rate, potentially worsening myocardial ischemia or precipitating a myocardial infarction (MI) [2]. Furthermore, these patients may require sublingual Nitroglycerin; the co-administration of nitrates and PDE-5 inhibitors is strictly contraindicated as it can cause life-threatening refractory hypotension. **Analysis of Incorrect Options:** * **A. Pulmonary arterial hypertension (PAH):** PDE-5 inhibitors are actually a standard treatment for PAH (e.g., Sildenafil/Revatio) because they promote pulmonary vasodilation and reduce pulmonary vascular resistance. * **C. Previous MI > 6 weeks ago:** Patients with a history of MI can safely use PDE-5 inhibitors provided they are currently stable, asymptomatic, and not on nitrate therapy. The high-risk period is generally considered the first 2–6 weeks post-event. * **D. Congestive heart failure (NYHA Class-I):** Patients with mild, stable heart failure (Class I) can generally tolerate these drugs [1]. Contraindications usually apply to severe (Class IV) or unstable heart failure. **High-Yield Clinical Pearls for NEET-PG:** * **The Nitrate Rule:** Avoid PDE-5 inhibitors for 24 hours after Sildenafil/Vardenafil and 48 hours after Tadalafil (due to its longer half-life) if nitrates are needed. * **Other Contraindications:** Recent stroke/MI (within 6 months), resting hypotension (<90/50 mmHg), and hereditary retinal degenerative disorders (e.g., Retinitis Pigmentosa). * **Side Effect:** "Blue-tinted vision" (Cyanopsia) due to cross-inhibition of PDE-6 in the retina.

Q: Which of the following drugs does not decrease angiotensin II activity?

Nesiritide. ### Explanation The question asks for the drug that does **not** decrease Angiotensin II (AT-II) activity. To answer this, one must distinguish between drugs that inhibit the Renin-Angiotensin-Aldosterone System (RAAS) and those that act on the Natriuretic Peptide system. **Why Nesiritide is the correct answer:** **Nesiritide** is a recombinant form of **B-type Natriuretic Peptide (BNP)**. Its primary mechanism is to increase intracellular cGMP, leading to potent vasodilation and natriuresis. While it counteracts the *effects* of the RAAS system physiologically, it does not directly decrease the production or receptor-binding activity of Angiotensin II. In fact, by causing vasodilation and potentially lowering blood pressure, it does not inherently inhibit the RAAS cascade. **Analysis of Incorrect Options:** * **Enalapril:** An **ACE Inhibitor**. It directly prevents the conversion of Angiotensin I to Angiotensin II, thereby decreasing AT-II levels. * **Valsartan:** An **Angiotensin Receptor Blocker (ARB)**. It binds to and blocks the $AT_1$ receptor, directly decreasing the activity/binding of AT-II. * **Omapatrilat:** A **Vasopeptidase Inhibitor**. It inhibits both ACE and Neprilysin. By inhibiting ACE, it directly decreases the production of Angiotensin II. **Clinical Pearls for NEET-PG:** * **Omapatrilat** was never FDA-approved due to a high risk of **angioedema**, caused by a "double hit" of bradykinin accumulation (both ACE and Neprilysin break down bradykinin). * **Sacubitril/Valsartan (ARNI)** is the modern clinical successor to Omapatrilat; it combines a Neprilysin inhibitor with an ARB to avoid the angioedema risk associated with combining it with an ACEI. * **Nesiritide** is used in acutely decompensated heart failure but must be monitored for causing significant hypotension.

Question 1

All of the following electrocardiographic findings may represent manifestations of digitalis intoxication, EXCEPT?

Accepted Answer

Atrial flutter

Answer

Bigeminy

Answer

Junctional tachycardia

Answer

Atrial tachycardia with variable block

Question 2

Which of the following conditions precipitates Digoxin toxicity?

Accepted Answer

Hypokalemia

Answer

Hyperkalemia

Answer

Hypernatremia

Answer

Hyperphosphatemia

Question 3

All of the following statements are true about quinidine except?

Accepted Answer

It has no effect on myocardial K+ channels.

Answer

It blocks myocardial Na+ channels primarily in the open state.

Answer

It produces frequency dependent blockade of myocardial Na+ channels.

Answer

It delays recovery of myocardial Na+ channels.

Question 4

Postural hypotension and failure of ejaculation is most commonly seen in treatment with?

Accepted Answer

Guanethedine

Answer

Minoxidil

Answer

Propranolol

Answer

Sodium nitroprusside

Question 5

Which of the following is the best inotropic drug for use in right heart failure?

Accepted Answer

Milrinone

Answer

Dobutamine

Answer

Dopamine

Answer

Digoxin

Question 6

Which one of the following antihypertensive drugs is contraindicated in pregnancy?

Accepted Answer

Furosemide

Answer

Alpha methyldopa

Answer

Hydralazine

Answer

Nifedipine

Question 7

Which of the following is an active metabolite of another drug and is available as a separate drug for the treatment of angina?

Accepted Answer

Isosorbide mononitrate

Answer

Isosorbide dinitrate

Answer

Nitroglycerine

Answer

Propranolol

Question 8

Digitalis does not affect which parameter of the heart?

Accepted Answer

None of the above

Answer

Heart rate

Answer

Contractility

Answer

Coronary blood flow

Question 9

Use of Phosphodiesterase Inhibitors for erectile dysfunction is contraindicated in which of the following conditions?

Accepted Answer

Unstable/symptomatic angina

Answer

Pulmonary arterial hypertension

Answer

Previous myocardial infarction > 6 weeks ago

Answer

Congestive heart failure (NYHA Class-I)

Question 10

Which of the following drugs does not decrease angiotensin II activity?

Accepted Answer

Nesiritide

Answer

Enalapril

Answer

Valsartan

Answer

Omapatrilat

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?